Canada: Amendments To The Patented Medicines (Notice Of Compliance) Regulations And Food And Drug Regulations

On October 5, 2006, the government of Canada passed substantive amendments to the Patented Medicines (Notice of Compliance) Regulations (the PM(NOC) Regulations) and the data protection provisions of the Food and Drug Regulations (the FD Regulations).

According to the Regulatory Impact Analysis Statement (RIAS) issued by the government to explain the proposed amendments, the purpose of these amendments is to restore the balance between the rights of patent holding drug manufacturers (innovators) and the generic drug manufacturers (generics), in order to ensure a balance between the two policy goals of effectively protecting pharmaceutical inventions (in order to stimulate research and development) and keeping the cost of medicines down.

Although there are a number of changes to the PM(NOC) Regulations, two amendments were particularly significant: (i) a "frozen" patent register and (ii) refined patent listing requirements. In addition, one of the amendments to the FD Regulations (the Data Protection Amendments), which provides for a six-year no-filing period for generic manufacturers and a minimum of an eight-year period of market exclusivity to innovators, is of particular importance.

PM(NOC) Regulations Amendments

The PM(NOC) Regulations provide for a framework permitting pharmaceutical patents to be listed on Health Canada’s patent register. The Regulations link the Minister of Health’s ability to approve a generic drug to the patent status of the innovator’s product by requiring the generic to address the patents listed on the patent register before a notice of compliance (NOC) is issued by the Minister.

If a generic serves an innovator with a notice of allegations (NOA), alleging that each of the patents on the register are not infringed by the generic or are invalid, the innovator may bring an application to the Federal Court to prohibit the Minister from issuing an NOC to the generic. Once such an application has been made, an automatic twenty-four-month stay comes into in effect. This prevents the Minister from issuing the NOC to the generic until the issues of infringement and invalidity are addressed.

Frozen Patent Register

Prior to these amendments, if a patent was added to the patent register after the generic had filed an abbreviated new drug submission (ANDS) for an NOC, but before the NOC was issued, the generic had to amend the ANDS and serve a new NOA in order to address the newly added patent. This process—sometimes referred to as "evergreening"— effectively gave innovators the ability to invoke multiple twenty-four-month stays in order to extend the terms of their monopolies.

Under the amendments, the patent register is now "frozen" as of the date of filing of the generic’s ANDS. The generic no longer needs to address any patents listed on the register by the innovator subsequent to that date: only patents that are on the register at the time of its drug submission need to be adressed. For submissions filed prior to October 5, 2006, the patent register is considered frozen as of October 5, 2006.

The "freezing" of the patent register is considered by many to be a significant gain for the generics.

Refined Listing Requirements

The amendments also refine the listing requirements under s. 4 of the PM(NOC) Regulations. Under the new requirements, a patent can be listed on the patent register with a new drug submission (NDS) if it contains a claim for the medicinal ingredient itself, the formulation, the dosage form, or a claim for a use of the medicinal ingredient. Each of these claims must be approved claims.

The amendments also increase the scope of eligible subject matter for patents to be listed. Previously, courts have consistently held that "claim for the medicine itself" in s. 4 was insufficient to support the listing of dosage form patents. The amendments contain explicit language changing the allowable subject matter to include dosage form patents.

Prior to the amendments, a patent could be listed with almost any supplement to a new drug submission (SNDS), with the exception of an SNDS filed for an administrative change such as a name change. Under the new requirements, a patent that has been applied for prior to the filing of a SNDS may be submitted with the SNDS, provided the purpose of the SNDS is to obtain approval for a change in the use of the medicinal ingredient, formulation, or dosage form. In addition, the patent can only be listed if it claims the use of the medicinal ingredient, formulation, or dosage form for which approval is sought.

It has been argued, notwithstanding the expansion of subject matter to include dosage form patents, that the new listing requirements are far stricter than the previous regulations, and thus, a loss for the innovators.

The new patent listing eligibility requirements do not apply to patents listed before June 17, 2006.

Data Protection Amendments

The Data Protection Amendments are intended to clarify and effectively implement Canada's obligations under the North American Free Trade Agreement and the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement with respect to data protection. These obligations require that signatories provide protection against the unfair commercial use of undisclosed tests or other data submitted in order to obtain approval of pharmaceutical or agricultural chemical products that utilize new chemical entities. The intent of this protection is to allow the originator of the data to protect the investments made in the development of the product by allowing a period of market exclusivity.

Under the previous FD Regulations, data protection arises when the Minister examines and relies on an innovator's undisclosed data in order to grant a NOC to a generic. The previous data protection provisions were intended to guarantee the confidentiality and non-use of the innovator’s data for a period of five-years from the date of issuance of the NOC to the innovator. However, to receive an NOC in Canada, a generic need only demonstrate bioequivalence by comparing its generic product to the innovator's product. Therefore, in actual practice, the Minister typically does not examine the data contained in the innovator's submission in order to grant a NOC for a generic product. As a result, data protection did not arise where bioequivalence formed the basis of a generic submission (see Bayer v. Attorney General of Canada (1999), 87 C.P.R. (3d) 293 (Federal Court of Appeal)).

The FD Regulations have been amended to prohibit the granting of a NOC to a generic for eight years from the issuance of the innovator’s NOC. A six-month extension is added to this time if the innovator designed and conducted clinical trials for use of the drug in paediatric populations. In addition, within the eight-year period, the generic is not able to file a drug submission until six years after the date in which the NOC was issued to the innovator. The amendments also require the Minister to maintain a register of innovative drugs.

These amendments have been considered a significant win for innovators. Combined with another amendment to the PM(NOC) Regulations that prohibits a NOA from being filed until an ANDS has been submitted to the Minister, these amendments provide the innovator with a six-year period to get all relevant patents issued and listed on the register.

The Data Protection Amendments apply to drugs that have received an NOC on or after June 17, 2006. If a generic has already filed a submission for a generic version of a drug that would otherwise benefit from the new data-protection term, the filing date of the submission will be deemed to be six years from the day on which the first NOC was issued for the innovative drug.

The Canadian Generic Pharmaceutical Association has recently announced the launch of a suit in Federal Court, which requests that the Federal Court quash the provisions of the PM(NOC) Regulations which give innovator drug firms additional years of data protection.

Additional Amendments

Detailed information regarding several other amendments to the PM(NOC) Regulations and FD Regulations are available online at the websites below.

PM(NOC) Regulations

FD Regulations

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions